Aquestive Therapeutics Inc AQST Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.78 down $0.28, 6.90% at close Oct 16
Last close · Previous close $4.06
- Market cap
- At the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.66Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$3.78down $0.28, 6.90%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$4.06Oct 15
- Volume5.23MOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.29MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.93 to $7.55; now $3.78
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
AQST beat the S&P 500 in 1 of 6 periods.
| Period | AQST and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AQST: down 21.6% S&P 500: up 1.5% | AQST trailed the S&P 500 by 23.1 percentage points Trailed |
| 3M | AQST: down 4.1% S&P 500: up 1.9% | AQST trailed the S&P 500 by 6.0 percentage points Trailed |
| YTD | AQST: down 41.5% S&P 500: up 12.8% | AQST trailed the S&P 500 by 54.3 percentage points Trailed |
| 1Y | AQST: down 46.1% S&P 500: up 16.8% | AQST trailed the S&P 500 by 62.9 percentage points Trailed |
| Long term | ||
| 3Y | AQST: up 118.5% S&P 500: up 81.5% +29.8% vs +22.0% a year | AQST beat the S&P 500 by 37.0 percentage points Beat |
| 5Y | AQST: down 2.3% S&P 500: up 83.1% −0.5% vs +12.9% a year | AQST trailed the S&P 500 by 85.4 percentage points Trailed |
$10,000 invested in AQST 5 years ago (Oct 15, 2021) would be worth about $9,767 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $18,305.
AQST beat the S&P 500 in 1 of 6 periods.
| Period | AQST and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AQST: down 21.6% S&P 500: up 1.2% | AQST trailed the S&P 500 by 22.8 percentage points Trailed |
| 3M | AQST: down 4.1% S&P 500: up 1.7% | AQST trailed the S&P 500 by 5.8 percentage points Trailed |
| YTD | AQST: down 41.5% S&P 500: up 11.9% | AQST trailed the S&P 500 by 53.4 percentage points Trailed |
| 1Y | AQST: down 46.1% S&P 500: up 15.5% | AQST trailed the S&P 500 by 61.6 percentage points Trailed |
| Long term | ||
| 3Y | AQST: up 118.5% S&P 500: up 75.0% +29.8% vs +20.5% a year | AQST beat the S&P 500 by 43.5 percentage points Beat |
| 5Y | AQST: down 2.3% S&P 500: up 71.2% −0.5% vs +11.4% a year | AQST trailed the S&P 500 by 73.5 percentage points Trailed |
$10,000 invested in AQST 5 years ago (Oct 15, 2021) would be worth about $9,767 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $17,118.
All-time high
$18.96
Closing high on . Now 80.1% below that record.
Split-adjusted daily closes since Jul 25, 2018.
Stock splits
AQST hasn’t split since its price history begins in 2018.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $54.09Mup 22.6%
- Net income
- −$78.23M
- Diluted EPS
- −$0.66
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $13.54M | −$11.51M | −$0.13 |
| Q4 FY24 (Dec 31, 2024) | $11.87M | −$17.06M | −$0.19 |
| Q1 FY25 (Mar 31, 2025) | $8.72M | −$22.93M | −$0.24 |
| Q2 FY25 (Jun 30, 2025) | $10.00M | −$13.55M | −$0.14 |
| Q3 FY25 (Sep 30, 2025) | $12.81M | −$15.45M | −$0.14 |
| Q4 FY25 (Dec 31, 2025) | $13.02M | −$31.86M | −$0.27 |
| Q1 FY26 (Mar 31, 2026) | $14.45M | −$8.06M | −$0.07 |
| Q2 FY26 (Jun 30, 2026) | $13.82M | −$22.86M | −$0.18 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $50.83M | −$70.54M | −$1.85 |
| FY22 (Dec 31, 2022) | $47.68M | −$54.41M | −$1.12 |
| FY23 (Dec 31, 2023) | $50.58M | −$7.87M | −$0.13 |
| FY24 (Dec 31, 2024) | $57.56M | −$44.14M | −$0.51 |
| FY25 (Dec 31, 2025) | $44.55M | −$83.78M | −$0.78 |
Margins
- Gross 67.0%
- Operating −97.5%
- Net −144.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$45.95MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$45.37MLast 12 months
- Capital spending$584.00KLast 12 months
- −85.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $86.95MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $98.49MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$149.03MAs of Jun 30, 2026
- Net debt$50.54MAs of Jun 30, 2026
- 7.19As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −52.4%Last 12 months
Over the last 12 months, Aquestive Therapeutics’s net loss was 52.4% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Aquestive Therapeutics Inc
Aquestive is pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm ®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AQST news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AQST stock FAQ
What is AQST stock’s price today?
Aquestive Therapeutics (AQST) traded at $3.78 at the close on , down $0.28 (6.90%) from the previous close of $4.06. Over the past 52 weeks it has traded between $2.93 and $7.55.
If you invested $1,000 in AQST 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in AQST on would be worth about $977 at the close on , a total return of −2.3%. The same $1,000 would be worth $539 if invested one year ago. Past performance doesn’t predict future returns.
What is AQST’s P/E ratio?
AQST’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.66).
How much revenue does Aquestive Therapeutics make?
Aquestive Therapeutics reported $54.1 million of revenue over the four quarters to , up 22.6% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $13.8 million, up 38.1% from a year earlier.
Is Aquestive Therapeutics profitable?
Not over the four quarters to . Aquestive Therapeutics reported a net loss of $78.2 million across those four quarters on $54.1 million of revenue.
What are AQST’s earnings per share?
AQST’s diluted earnings per share were −$0.66 over the four quarters to , compared with −$0.70 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.18 per share, against −$0.14 a year earlier (how EPS works).
Does AQST pay a dividend?
Aquestive Therapeutics hasn’t paid a dividend in the last twelve months.
What is AQST’s 52-week high and low?
Over the past 52 weeks AQST has traded as low as $2.93 and as high as $7.55. At $3.78 at the close on , it is 49.9% below that high and 29.0% above the low.
What is AQST’s all-time high?
AQST’s highest closing price was $18.96 on , adjusted for stock splits. At $3.78 at the close on , it is 80.1% below that record.
Has AQST stock ever split?
No. AQST hasn’t split since its price history begins in 2018.
How has AQST stock performed?
Including dividends and measured to the close on , AQST has returned −41.5% so far this year and −46.1% over the past year, and −2.3% over five years (−0.5% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Aquestive Therapeutics in?
Aquestive Therapeutics is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in New Jersey, USA.
What exchange does AQST trade on?
Aquestive Therapeutics trades on the Nasdaq under the ticker symbol AQST. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.